M Patricia Rivera (University of North Carolina in Chapel Hill, NC, US) is Chair of the ATS Assembly on Thoracic Oncology. Here she discusses the mission and scope of her Assembly, significant recent developments in her field and activities at ATS 2018 that have been of greatest interest.
1. Tell us a little about the Assembly on Thoracic Oncology (0:11)
2. What have been the most significant recent developments in your field? (1:02)
3. What activities/presentations at ATS 2018 are of greatest interest to your assembly? (3:52)
Speaker disclosure: M Patricia Rivera has nothing to disclose in relation to this video interview.
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Share this Video
Related Videos In Lung Cancer
A study of varenicline and nicotine replacement therapy for smokers admitted to hospital in Australia: Michael Abramson, ERS 2023
Varenicline was approved as a replacement therapy for smoking back in 2007 in Australia, the uptake for varenicline has remained high despite issues associated with patient adherence and access to the therapy. In this interview, touchRESPIRATORY were delighted to speak with Prof. Michael Abramson (Monash University, Victoria, Australia) to discuss his randomized, placebo-controlled trial evaluating […]
Daniel Steinfort, WCBIP 2022: Findings from the SEISMIC Study
The SEISMIC study investigated lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with locally advanced non-small cell lung cancer (NSCLC). touchRESPIRATORY were delighted to speak with Dr. Daniel Steinfort (Royal Melbourne Hospital, Melbourne, Australia) to learn more around the aims, design and findings from the study and the importance of these findings […]
Paulo Rodrigues Santos, ERS 2022: Immunosuppressive Factors Affecting Anti-PD-1 Therapy in Phase IIIB/IV Non-small Cell Lung Cancer
touchRESPIRATORY caught up with Dr. Paulo Rodrigues Santos (University of Coimbra, Coimbra, Portugal) to discuss the challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer, the cellular and plasmatic immunosuppressive factors that affect the outcome of anti-PD-1 therapy and the data supporting the strategies used to overcome these immunosuppressive […]